Person: FİLİNTE, DENİZ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
FİLİNTE
First Name
DENİZ
Name
8 results
Search Results
Now showing 1 - 8 of 8
Publication Metadata only Is Cognitive MR Fusion Biopsy Superior to Standard TRUS Guided Prostate Biopsy? Our Clinical Experience(2022-06-01) FİLİNTE, DENİZ; ÇAM, HAYDAR KAMİL; ŞAHİN, BAHADIR; DÖRÜCÜ, DOĞANCAN; ŞAHİN B., DÖRÜCÜ D., TİNAY İ., FİLİNTE D., ÇAM H. K.Objective: To share our clinical experience with cognitive prostate biopsy and compare results of cognitive biopsies with standard biopsies.Publication Metadata only Urinary micro-RNA expressions and protein concentrations may differentiate bladder cancer patients from healthy controls(SPRINGER, 2020) ILGIN, CAN; Amuran, Gokce Gullu; Tinay, Ilker; Filinte, Deniz; Ilgin, Can; Eyuboglu, Irem Peker; Akkiprik, MustafaPurpose To determine expression differences of urine exosomal miR-19b1-5p, 21-5p, 136-3p, 139-5p, 210-3p and concentration differences of urinary BLCA-4, NMP22, APE1/Ref1, CRK, VIM between bladder cancer, follow-up patients, and control samples, to evaluate diagnostic importance of these differences and establish a diagnostic panel for bladder cancer. Methods Urine samples of 59 bladder cancer patients, 34 healthy controls, and 12 follow-up patients without recurrence were enrolled to this study. Real-time PCR and ELISA were performed to determine urine exosomal miR-19b1-5p, 21-5p, 136-3p, 139-5p, 210-3p expressions and urinary BLCA-4, NMP22, APE1/Ref1, CRK, VIM, creatinine concentrations. Logistic regression analyses were performed to determine the diagnostic panel, the sensitivity, and specificity of the panel assessed by the ROC curve analysis. p values < 0.05 were considered statistically significant. Results In bladder cancer risk groups, mir-139, -136, -19 and 210 expressions or positivity were found to be different and concentrations of urinary Ape1/Ref1, BLCA4, CRK, and VIM increased by twofold on average compared to healthy controls. Logistic regression and ROC analyses revealed that panel could differentiate bladder cancer patients from healthy controls with 80% sensitivity and 88% specificity (AUC = 0.899), low-risk patients from controls with 93% sensitivity and 95.5% specificity (AUC = 0.976). Despite the low number of samples, our findings suggest that urine exosomal miR-19b1-5p, 136-3p, 139-5p expression, and urinary APE1/Ref1, BLCA-4, CRK concentrations are promising candidates in terms of bladder cancer diagnosis. Conclusions Although our panel has great sensitivity for early detection of BC, it needs to be validated in larger populations.Publication Open Access Atypical Cell'' Parameter in Automated Urine Analysis for the Diagnosis of Bladder Cancer: A Retrospective Pilot Study(GALENOS YAYINCILIK, 2020-04-01) FİLİNTE, DENİZ; Tinay, Ilker; Sahin, Bahadir; Saracoglu, Sertac; Yanilmaz, Ozgur; Aksu, Mehmet Burak; Ayas, Ramazan; Filinte, Deniz; Cam, Haydar Kamil; Ilki, ArzuObjective: To evaluate the application of an automated urine analyzer (AUA) for the diagnosis of bladder cancer (BC) Materials and Methods: A retrospective data analysis of 2365 urine specimens from the department of urology has been performed and matched with those patients, who have undergone cystoscopic evaluation or surgical treatment for different urological pathologies during 2018. After matching, clinical records of the patients has been further evaluated in order to select patients with recent or previous BC diagnosis. To assess the diagnostic efficacy of AUA, patients were divided into five groups according to the patient history of BC and healthy controls. Results: A total of 106 patients are included in this study and the majority (69.8%) of the patients are follow-up patients with previous diagnosis and treatment of non-muscle invasive BC (NMIBC). For patients with low-risk NMIBC (n=27), the sensitivity and specificity were calculated as 75% and 100%. For patients with high-risk NMIBC (n=47), who were previously treated with intravesical BCG, the sensitivity and specificity were calculated as 54.5% and 83.3%. All patients in radical cystectomy group (n=7) with muscle invasive BC had positive urine analyses results for atypical cells. And none of the patients in the control group (n=8) had positive AUA results and cystoscopic evaluation also did not show any bladder mass suspicious for BC. Conclusion: The results of this retrospective pilot study showed acceptable sensitivity and specificity rates of the fluorescence flow cytometry based AUA and the results of the low-risk group are especially valuable regarding its potential use to decide on performing a follow-up cystoscopy or not. A prospective study is currently on progress to validate the findings of the current study.Publication Open Access Risk factors of patients with prostate cancer upgrading for international society of urological pathology grade group I after radical prostatectomy(2022-01-01) ÖZGÜR, GÜNAL; FİLİNTE, DENİZ; ÇAM, HAYDAR KAMİL; ÖZGÜR A., ÖZGÜR G., ŞAHİN B., FİLİNTE D., TİNAY İ., ÇAM H. K., TÜRKERİ N. L.Objective: This study aimed to determine the predictive factors for patients whose International Society of Urological Pathology (ISUP) score was upgraded in radical prostatectomy (RP) pathologies with a prostate biopsy pathology of ISUP grade group 1. Materials and Methods: Among patients who underwent RP in our clinic within 10 years, 158 patients with prostate biopsy pathology of ISUP grade group 1 were examined retrospectively. Age, serum prostate-specific antigen (PSA) level, prostate biopsy ISUP grade group, number of cores taken in the prostate biopsy, number of tumor-positive cores, RP pathology ISUP grade group, and pathological stage were evaluated. Results: The mean age (± standard) of the 158 patients whose prostate biopsy pathology was ISUP grade group 1 were 64.07 (±6.6). ISUP group upgrading was detected in 47 patients (29.7%). The mean PSA value of these patients was 10.6 ng/mL (±6.9). The mean PSA value of the other 111 patients without ISUP group upgrading was 7.98 ng/mL (±4.9). The serum PSA level was significantly higher in patients with upgraded ISUP in the RP pathology (p=0.02). The percentage of tumor-positive cores in the group with ISUP group upgrading (37%) was significantly higher than that in the group without ISUP group upgrading (27%) (p=0.01). The detection rates of surgical margin positivity (42.6% vs. 18%), capsule invasion (55.3% vs. 19.8%), and seminal vesicle invasion (23.6% vs. 3.6%) were also significantly higher in the upgraded ISUP group after RP (p<0.05). Conclusion: The results of this trial suggest that active surveillance may not be an appropriate option for patients with biopsy ISUP grade group 1 with PSA level >10 ng/mL. Moreover, the presence of a higher number and percentage of tumor-positive cores constituted risks of ISUP group upgrading with concomitant poor pathological outcomes such as surgical margin positivity, capsule invasion, and seminal vesicle invasion.Publication Open Access Histopathologic and spectrometric evaluation of bony components of synostotic suture and parietal bone in children with sagittal synostosis(2023-01-01) FİLİNTE, DENİZ; CICEK C., FILINTE G., HICDONMEZ T., AMUTKAN MUTLU D., FİLİNTE D., SULUDERE Z.AIM: To understand the characterization of the ossification process both in the synostotic suture, and the adjacent parietal bone. MATERIAL and METHODS: The surgical procedure for the 28 patients diagnosed with sagittal synostosis consisted of removing the synostotic bone as a whole, if possible, \"Barrel–Stave\" relaxation osteotomies, and strip osteotomies to the parietal and temporal bones perpendicular to the synostotic suture. The synostotic (group I) and parietal (group II) bone segments are obtained during osteotomies. Atomic absorption spectrometry was used to determine the amount of calcium in both groups, which is an indicator of ossification. Scanning electron microscopy and immunohistochemistry were employed to assess trabecular bone formation, osteoblastic density, and osteopontin, which is one of the in vivo indicators of new bone formation. RESULTS: Histopathologically, trabecular bone formation scores did not indicate any significant difference between the groups. However, the osteoblastic density and calcium accumulation in group I were higher than those in group II, and the difference was significant. Osteopontin staining scores in cells showing membranous and cytoplasmic staining with osteopontin antibodies significantly increased in group II. CONCLUSION: In this study, we found reduced differentiation of osteoblasts despite their increase in number. Moreover, the osteoblastic maturation rate was low in synostotic sutures, bone resorption becomes slower than new bone formation, and the remodeling rate is low in sagittal synostosis.Publication Open Access Catastrophic antiphospholipid syndrome accompanied by complement regulatory gene mutation(2023-03-01) GÖKCE, İBRAHİM; DEMİRCİ BODUR, ECE; ÇİÇEK DENİZ, NESLİHAN; SAK, MEHTAP; FİLİNTE, DENİZ; ALPAY, HARİKA; Pul S., GÖKCE İ., DEMİRCİ BODUR E., Guven S., ÇİÇEK N., SAK M., Turkkan O. N., FİLİNTE D., Pehlivanoglu C., Sozeri B., et al.Background. Antiphospholipid syndrome (APS), particularly the catastrophic antiphospholipid syndrome (CAPS), is one of the rare causes of thrombotic microangiopathy (TMA). CAPS is the most severe form of APS, especially when accompanied by complement dysregulation, causes progressive microvascular thrombosis and failure in multiple organs. In this report, a case of CAPS with TMA accompanied by a genetic defect in the complement system is presented.Case. A 13-year-old girl was admitted to the hospital with oliguric acute kidney injury, nephrotic range proteinuria, Coombs positive hemolysis, refractory thrombocytopenia, a low serum complement C3 level and anti-nuclear antibody (ANA) positivity. The kidney biopsy was consistent with TMA. She was first diagnosed with primary APS with clinical and pathological findings and double antibody positivity. As initial treatments, plasmapheresis (PE) was performed and eculizumab was also administered following pulse -steroid and intravenous immunoglobulin treatments. Her renal functions recovered and she was followed up with mycophenolate mofetil, hydroxychloroquine, low dose prednisolone and low molecular weight heparin treatments. The patient presented with severe chest pain, vomiting and acute deterioration of renal functions a few months after the diagnosis of TMA. A CAPS attack was considered due to radiological findings consistent with multiple organ thrombosis and intravenous cyclophosphamide (CYC) was given subsequent to PE. After pulse CYC and PE treatments, her renal functions recovered, she is still being followed for stage-3 chronic kidney disease. Complement factor H-related protein I gene deletion was detected in the genetic study.Conclusions. The clinical course of complement mediated CAPS tends to be worse. Complement system dysregulation should be investigated in all CAPS patients, and eculizumab treatment should be kept in mind if detected.Publication Metadata only How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature(SAGE PUBLICATIONS LTD, 2020) FİLİNTE, DENİZ; Alan, Ozkan; Kuzhan, Okan; Koca, Sinan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Ercelep, Ozlem; Filinte, Deniz; Sengul, Yildiz; Arikan, Huseyin; Kaya, Serap; Babacan, Nalan Akgul; Dane, Faysal; Yumuk, Perran FuldenIntroduction: Inflammatory myofibroblastic tumor is a rare disease which is typically seen in children and young adults. Approximately half of the inflammatory myofibroblastic tumors contain translocations that result in over-expression of anaplastic lymphoma kinase gene. Herein, we present two anaplastic lymphoma kinase-positive cases with long-term remission with crizotinib. We do not know how long these therapies need to be continued. Case reports: We present two cases of inflammatory myofibroblastic tumor treated with anaplastic lymphoma kinase inhibitor therapies: an 8-year-old Turkish boy and a 21-year-old Caucasian man. Management and outcome: Two cases, both with good tumor control under crizotinib, but one who progressed on drug holiday, responded again to the same drug, and had a very short period of response after restarting crizotinib. Conclusion: A molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammatory myofibroblastic tumor with anaplastic lymphoma kinase translocation. Here, we want to emphasize the continuation of this treatment after achieving a good response until progression or a major side effect.Publication Open Access Renal Amyloidosis Secondary to Dystrophic Epidermolysis Bullosa: A Case Report and Review of Literature(2020-10-20) VELİOĞLU, ARZU; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Barutcu Atas, Dilek; Aykent, Mahmut Basar; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Arikan, Izzet Hakki; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Asicioglu, Ebru; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Velioglu, Arzu; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Filinte, Deniz; Department of Pathology, Marmara University School of Medicine, Istanbul, Turkey; Koc, Mehmet; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Serhan Tuglular, Zubeyde; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; Ozener, Ishak Cetin; Division of Nephrology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey